Analyst Price Target is $19.67
▲ +408.18% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aridis Pharmaceuticals in the last 3 months. The average price target is $19.67, with a high forecast of $22.00 and a low forecast of $18.00. The average price target represents a 408.18% upside from the last price of $3.87.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Aridis Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in Los Gatos, CA.